Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids,

Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Scleroderma is a chronic condition which commonly affects the skin and connective tissue. Scleroderma is an autoimmune disorder wherein the immune system of the body produces extra collagen protein which gets deposited in the tissues and causes hardening of skin. Collagen is a fibrous protein which is found abundantly in the body to provide strength and structure to the body. The two major forms of scleroderma include localized and systemic. In localized scleroderma, only the skin is affected and not any organs while in systemic scleroderma, the skin and the underlying tissues under it are affected. Systemic scleroderma affects blood vessels and major organs of the body such as heart, lungs, kidneys, gastrointestinal tract, and others. Systemic scleroderma can be classified into three major types namely, limited systemic sclerosis, diffused systemic sclerosis, and systemic sclerosis sine scleroderma. Limited scleroderma is one of the most common type of systemic scleroderma wherein, the hardening effect of the disease is limited to fingers and it is less likely to cause internal organ damage. In diffused systemic sclerosis, body parts such as fingers, hands, arms, anterior trunk, legs, and face are affected. Diffused systemic sclerosis also affects internal organs such as heart and lungs. In systemic sclerosis sine scleroderma, no skin thickening is seen but internal organs such as heart, kidney, and lungs may get severely damaged.
Market Dynamics
The increasing prevalence of scleroderma, rising research and development activities for the development of novel therapeutics for the treatment of scleroderma, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global systemic scleroderma treatment market over the forecast period.
For instance, according to a review article published by the Rheumatology Journal of the British Society for Rheumatology in February 2021, the pooled global prevalence of scleroderma was estimated to be 17.6 per 100,000 people in 2021 and is expected to increase in the near future.
Key features of the study:
This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global systemic scleroderma treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market
Detailed Segmentation:
Global Systemic Scleroderma Treatment Market, By Drug Class:
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
Global Systemic Scleroderma Treatment Market, By Disease Type:
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
Global Systemic Scleroderma Treatment Market, By Route of Administration:
Oral
Parenteral
Global Systemic Scleroderma Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Systemic Scleroderma Treatment Market, By Region:
North America
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Immunosuppressors
Calcium Channel Blockers
Proton Pump Inhibitors
Phosphodiesterase 5 Inhibitors
Endothelin Receptor Antagonists
Prostacyclin Analogues
Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
By Disease Type
Limited Systemic Sclerosis
Diffused Systemic Sclerosis
Systemic Sclerosis Sine Scleroderma
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Bristol-Myers Squibb Company*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Corbus Pharmaceuticals
Actelion Pharmaceuticals Ltd.
Allergan
F. Hoffmann-La Roche Ltd.
Biogen
Novartis AG
AstraZeneca
Celgene Corporation
Ono pharmaceutical co. Ltd.
Teva Pharmaceutical Industries Ltd.
Aspen Holdings
Pfizer Inc.
Eli Lilly and Company
Bayer AG
Amgen Inc.
Sanofi
Argentis Pharmaceuticals, LLC
“*” marked represents similar segmentation in other categories in the respective section.